Arrowhead Pharmaceuticals, Inc. (ARWR) |
|
45.88 -1.75 (-3.67%)
|
08-18 06:31 |
|
Open: |
46.83 |
Pre. Close: |
47.63 |
|
High:
|
47.13 |
Low:
|
45.75 |
|
Volume:
|
457,036 |
Market Cap:
|
4,856(M) |
|
|
|
|
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
47.15 - 47.47 |
47.47 - 47.73 |
|
Low:
|
45.15 - 45.45 |
45.45 - 45.71 |
|
Close:
|
45.43 - 45.93 |
45.93 - 46.34 |
|
Technical analysis |
as of: 2022-08-17 4:21:30 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 56.62 One year: 66.13 |
| Support: |
Support1: 43.66  Support2: 40.68 |
| Resistance: |
Resistance1: 48.47 Resistance2: 56.62 |
| Pivot: |
45.38 |
| Moving Average: |
MA(5): 46.94 MA(20): 44.77
MA(100): 39.6 MA(250): 52.1 |
| MACD: |
MACD(12,26): 1.9 Signal(9): 1.9 |
| Stochastic oscillator: |
%K(14,3): 83.1 %D(3): 86.5 |
| RSI: |
RSI(14): 56.1 |
| 52-week: |
High: 84.83 Low: 26.8 |
| Average Vol(K): |
3-Month: 823 (K) 10-Days: 721 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ARWR ] has closed below upper band by 43.7%. Bollinger Bands are 16.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Wed, 17 Aug 2022
Arrowhead Pharmaceuticals Inc. (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis - StreetInsider.com
Sun, 14 Aug 2022
State Board of Administration of Florida Retirement System Sells 2730 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Tue, 09 Aug 2022
ARWR: Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates… - Benzinga
Fri, 05 Aug 2022
Arrowhead Pharmaceuticals (ARWR) Q3 2022 Earnings Call Transcript - The Motley Fool
Thu, 04 Aug 2022
Arrowhead Pharmaceuticals GAAP EPS of -$0.68 misses by $0.21, revenue of $32.41M misses by $20.2M (NASDAQ:ARWR) - Seeking Alpha
Thu, 28 Jul 2022
Arrowhead Pharmaceuticals: An RNAi Name To Know (NASDAQ:ARWR) - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
106 (M) |
| Shares Float |
103 (M) |
|
% Held by Insiders
|
2.6 (%) |
|
% Held by Institutions
|
67.1 (%) |
|
Shares Short
|
4,930 (K) |
|
Shares Short P.Month
|
4,980 (K) |
Stock Financials |
|
EPS
|
-1.09 |
|
EPS Est Next Qtl
|
-0.13 |
|
EPS Est This Year
|
-0.42 |
|
EPS Est Next Year
|
-0.67 |
|
Book Value (p.s.)
|
4.48 |
|
Profit Margin (%)
|
-61.6 |
|
Operating Margin (%)
|
-63.9 |
|
Return on Assets (ttm)
|
-13.5 |
|
Return on Equity (ttm)
|
-33.8 |
|
Qtrly Rev. Growth
|
-29.4 |
|
Gross Profit (p.s.)
|
1.3 |
|
Sales Per Share
|
2.36 |
|
EBITDA (p.s.)
|
-1.42 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-42.49 |
|
PEG Ratio
|
-5.3 |
|
Price to Book value
|
10.24 |
|
Price to Sales
|
19.41 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
